Diametric Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Diametric Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,843	Closed	-$352K	–	115
2018 Q4	$352K	Sell	2,843 -9,701	-77%	-$1.44M	0.27%	85
2018 Q3	$2.11M	Buy	+12,544	New	+$2.16M	1.83%	15
2018 Q1	–	Sell	-7,788	Closed	-$1.05M	–	104
2017 Q4	$1.05M	Buy	+7,788	New	+$1.08M	0.64%	68

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Diametric Capital's JAZZ Position: Q1 2019 in Review

Diametric Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 2,843 shares — an estimated $352K sold.

Diametric Capital first reported a position in JAZZ in Q4 2017 and held it in 3 quarters. The position peaked at $2.11M in Q3 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Diametric Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Diametric Capital sold 2,843 Jazz Pharmaceuticals shares in Q1 2019, an estimated $352K.
Diametric Capital first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Diametric Capital's Jazz Pharmaceuticals position peaked at $2.11M in Q3 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Diametric Capital's 13F filing for Q1 2019, filed 15 May 2019.